A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus

Phase 1/2 Not yet recruiting 159 enrolled Sinocelltech Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SCTC21C in participants with systemic lupus erythematosus

Timeline

Start: 2026-04
Primary completion: 2027-04
Completion: 2028-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SCTC21C	Unknown	—	Subcutaneous

A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus

Summary

Timeline

Drugs

Indications